BIIB34:BVMF
Biogen Inc BDR
R$ 230.10
0.00%
(0.00) 1D
11-р сарын 4, 15:38:07 (GMT-3) · BRL
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BIIB34...
Mkt. cap
36.71 тэрбум
Avg. vol.
9.00
Volume
0.00
52-wk high
R$ 230.10
52-wk low
R$ 137.90
Shares outstanding
147.82 сая
No. of employees
8 мян
Mkt. cap
36.71 тэрбум
Avg. vol.
9.00
Volume
0.00
52-wk high
R$ 230.10
52-wk low
R$ 137.90
Shares outstanding
147.82 сая
No. of employees
8 мян
News stories
From web sources and news partners
Yahoo Finance
·
52 минутын өмнө
Tech stocks are now cheaper than the S&P 500 for the first time since 2017 — here's what history says comes next: Chart of the Day
Investing.com
·
42 минутын өмнө
Poland’s Domanski blames presidential vetoes as S&P cuts outlook to negative
WTNH.com
·
24 минутын өмнө
From high-flying AI stocks to tariff-hit alcohol companies, the midterms shook up Wall Street
Fox Business
·
16 цагийн өмнө
Nasdaq rallies as chip stocks recover from brutal losses
Profile
Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs.
The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000. Wikipedia
About Biogen Inc BDR
CEOChris Viehbacher
Employees7.5 мян
Founded1978
HeadquartersКембриж, Массачусеттс, Америкийн Нэгдсэн Улс
SectorHealth Care
Industry-
Websitebiogen.com